Key result
Higher lymphocyte-to-CRP ratio linked to ~30% lower likelihood of subclinical myocardial injury in men.
Why the study?
The clinical utility of lymphocyte-to-C-reactive protein ratio (LCR) in identifying subclinical myocardial injury risk in individuals free from cardiovascular disease requires further validation.
Is a higher lymphocyte-to-C-reactive protein ratio associated with a reduced risk of subclinical myocardial injury in a general population free from cardiovascular disease?
Cross-Sectional (n=5,870)
Is a higher lymphocyte-to-C-reactive protein ratio associated with a reduced risk of subclinical myocardial injury in a general population free from cardiovascular disease?
A higher lymphocyte-to-C-reactive protein ratio is inversely associated with subclinical myocardial injury exclusively in males without known cardiovascular disease, suggesting its potential utility as a sex-specific biomarker for early cardiovascular risk.
LCR may flag subclinical cardiovascular risk; leaves open clinical utility pending prospective validation.
BACKGROUND AND AIM: The Lymphocyte-to-C-reactive protein ratio (LCR) combines information on immune and inflammatory status. Lymphocytes reflect immune health, while C-reactive protein (CRP) signals systemic inflammation. Some studies have linked LCR with cardiovascular outcomes, suggesting it could help identify at-risk individuals. However, its clinical utility needs further research validation. To investigate the association between lymphocyte-to-C-reactive protein ratio (LCR) and subclinical myocardial injury (SC-MI) in individuals who are free from cardiovascular disease (CVD) within the general population. METHODS AND RESULTS: The study included individuals in the National Health and Nutrition Examination Survey (NHANES) III. SC-MI was defined as having a Cardiac Infarction Injury Score (CIIS) greater than 10 units on a 12-lead electrocardiogram. Logistic regression models were employed to investigate the association between LCR and SC-MI. In total, 5870 individuals were included in the study, among whom 3266 had a history of SC-MI. Compared with the lowest quartile (Q1) in male, the odds ratios (OR) of SC-MI in Q2, Q3, and Q4 were 0.67 (95%CI: 0.53-0.86), 0.66 (95%CI: 0.51-0.84), and 0.70 (95%CI: 0.55-0.89), respectively. The data shows a trend where the OR of SC-MI are lower in higher quartiles of LCR, compared to the lowest quartile, in the male population (P for trend = 0.006). In other words, the likelihood of SC-MI tends to be lower among males with higher LCR values. However, after adjusting for potential confounding variables, the relationship between LCR and SC-MI displays a pattern of an initial decline, followed by a minor upward shift. CONCLUSION: LCR is independently and inversely associated with SC-MI risk in the general population free from CVD. Furthermore, the observed association is exclusive to males, indicating a need for further randomized controlled trials to substantiate the efficacy of implementing LCR reduction as a means of CVD prevention in the male population.
No takes yet. Share an insight, caveat, or question.
He et al. (2023) conducted a cross-sectional in Subclinical myocardial injury (n=5,870). Lymphocyte-to-C-reactive protein ratio (LCR) vs. Lowest quartile (Q1) of LCR was evaluated on Subclinical myocardial injury (SC-MI) defined as Cardiac Infarction Injury Score (CIIS) > 10 units on a 12-lead electrocardiogram (OR 0.70, 95% CI 0.55-0.89, p=0.006). In males free from cardiovascular disease, a higher lymphocyte-to-C-reactive protein ratio was associated with a lower likelihood of subclinical myocardial injury (OR 0.70; 95% CI 0.55-0.89 for Q4 vs Q1; P for trend = 0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: